University of Minnesota. Driven to Discover.
Also, the NIAID has reached an agreement to license an experimental treatment.
The drug, zoliflodacin, was highly effective in treating urogenital and rectal infections but not pharyngeal cases.
Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.
Bacillus could be a tool to decolonize patients found to carry S aureus in their nose or intestines.
In another new development, the NIH today announced the start of the first human trial of a live attenuated vaccine against Zika.
The announcement comes as Nigeria is experiencing its largest outbreak, with 481 confirmed cases reported as of last week, 133 of them fatal.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyAcademic Health Center, University of Minnesota, Minneapolis, MN
© 2018 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.